Patents by Inventor Xiaojun Han

Xiaojun Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOCONJUGATES AND METHODS
    Publication number: 20260234219
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: November 12, 2025
    Publication date: August 13, 2026
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • CYCLIN K DEGRADER AND USE THEREOF
    Publication number: 20260209211
    Abstract: Provided are a Cyclin K degrader compound, and preparation method and uses thereof. Specifically, provided are the compounds represented by formula (I) and pharmaceutical compositions thereof, and use thereof for preventing and/or treating Cyclin K-related diseases.
    Type: Application
    Filed: December 13, 2023
    Publication date: July 23, 2026
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Beidi XU, Zhiyong YU, Xiaojun HAN, Xin CHANG, Qingchong QIU, Ling ZHANG, Yao WANG, Nanhai HE, Xiaohan WANG, Xiangyu XIA
  • EXATECAN IMMUNOCONJUGATES
    Publication number: 20260137795
    Abstract: Immunoconjugates of the Formula (I), or a pharmaceutically acceptable salt thereof, include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment, inhibition, or amelioration of a cancer.
    Type: Application
    Filed: January 25, 2024
    Publication date: May 21, 2026
    Inventors: Xiaojun Han, Kevin Duane Bunker, Kimberlee Fischer
  • Immunoconjugates and methods
    Patent number: 12545716
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: February 10, 2026
    Assignee: Immunome, Inc.
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • IMMUNOCONJUGATES AND METHODS
    Publication number: 20260021193
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: July 25, 2023
    Publication date: January 22, 2026
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Peter Qinhua Huang, Kevin Duane Bunker, Kimberlee Fischer
  • USE OF HETEROCYCLIC COMPOUND IN TREATING DISEASES RELATED TO KINASE DRUG-RESISTANT MUTATION AND METHOD THEREFOR
    Publication number: 20250268897
    Abstract: The present invention relates to a use of a heterocyclic compound represented by formula I in the preparation of a drug for treating or assisting the treatment of diseases or conditions in an individual relating to a rearranged during transfection (RET) drug-resistant mutation and a treatment method using said heterocyclic compound.
    Type: Application
    Filed: March 21, 2022
    Publication date: August 28, 2025
    Applicant: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    Inventors: Zhonghui Chen, Xiaoxi Yuan, Dongmei Lei, Runfeng Han, Xiaojun Han, Qiang Tian, Hongmei Song, Jingyi Wang
  • Immunoconjugates and methods
    Patent number: 12285492
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Grant
    Filed: August 30, 2024
    Date of Patent: April 29, 2025
    Assignee: Immunome, Inc.
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • Immunoconjugates and methods
    Patent number: 12280121
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Grant
    Filed: August 30, 2024
    Date of Patent: April 22, 2025
    Assignee: Immunome, Inc.
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • Immunoconjugates and methods
    Patent number: 12274754
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Grant
    Filed: August 30, 2024
    Date of Patent: April 15, 2025
    Assignee: Immunome, Inc.
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • Immunoconjugates and methods
    Patent number: 12268750
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Grant
    Filed: August 30, 2024
    Date of Patent: April 8, 2025
    Assignee: Immunome, Inc.
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • Immunoconjugates and methods
    Patent number: 12186403
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Grant
    Filed: October 2, 2023
    Date of Patent: January 7, 2025
    Assignee: Immunome, Inc.
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • IMMUNOCONJUGATES AND METHODS
    Publication number: 20240424123
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: August 30, 2024
    Publication date: December 26, 2024
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • IMMUNOCONJUGATES AND METHODS
    Publication number: 20240424121
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: August 30, 2024
    Publication date: December 26, 2024
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • IMMUNOCONJUGATES AND METHODS
    Publication number: 20240424124
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: August 30, 2024
    Publication date: December 26, 2024
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • IMMUNOCONJUGATES AND METHODS
    Publication number: 20240424122
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: August 30, 2024
    Publication date: December 26, 2024
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • IMMUNOCONJUGATES AND METHODS
    Publication number: 20240408225
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: August 30, 2024
    Publication date: December 12, 2024
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • IMMUNOCONJUGATES AND METHODS
    Publication number: 20240408224
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: August 30, 2024
    Publication date: December 12, 2024
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
    Patent number: 12097242
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: September 24, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides
    Patent number: 12097241
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: January 11, 2022
    Date of Patent: September 24, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • METHOD FOR PREPARING A POLYURETHANE COMPOSITE MATERIAL BY VACUUM INFUSION PROCESS
    Publication number: 20240165897
    Abstract: A method for treating a core material is provided. A method for preparing a composite material, the composite material prepared by the method, and the use thereof is also provided.
    Type: Application
    Filed: March 17, 2022
    Publication date: May 23, 2024
    Inventors: Ian Zheng, Yongming Gu, Di Wu, Xiaojun Han, Hui Zhang